Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid Expenses Other Current Assets [Text Block] Income Statement [Abstract] Operating expenses Operating Expenses [Abstract] General and administrative General and Administrative Expense Research and development expenses Research and Development Expense License expenses License Fee License Fee Impairment of goodwill Goodwill, Impairment Loss Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Other income Other Nonoperating Income (Expense) Net loss Net Income (Loss) Attributable to Parent Deemed dividend from trigger of round down provision feature Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount Net loss to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Foreign currency translation adjustments, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Loss per common share - basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Expense Research and Development Expense [Member] General and Administrative Expense General and Administrative Expense [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation expense Share-based Payment Arrangement, Expense Income Tax Disclosure [Abstract] Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Permanent differences Effective Income Tax Rate Reconciliation Permanent Differences Effective income tax rate reconciliation, permanent differences. Research and development credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Stock compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Other Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent Goodwill impairment Effective Income Tax Rate Reconciliation Goodwill Impairment Effective income tax rate reconciliation goodwill impairment. Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Accounting Policies [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Going Concern Liquidity Policy Policy [Text Block] Liquidity, policy. Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Risks and Uncertainties Risks And Uncertainties Policy [Text Block] Risks and uncertainties. Cash and Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Business Combinations Business Combinations Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Grant Funding and Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Indemnifications Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Document And Entity Information [Abstract] Document and entity information. Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] 2015 Stock Incentive Plan Two Thousand And Fifteen Stock Incentive Plan [Member] Two Thousand And Fifteen Stock Incentive Plan [Member] 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Amended And Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Award Type Award Type [Axis] Equity Award Award Type [Domain] Stock Options Share-based Payment Arrangement, Option [Member] Restricted Stock Restricted Stock [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Private Dare Private Dare [Member] Private Dare. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Reverse stock split Stockholders' Equity, Reverse Stock Split Reverse stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Stock options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Annual percentage increase in outstanding number of common stock Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Number of authorized shares, period increase Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Options to purchase number of outstanding shares of common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Unamortized stock-based compensation expense Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Amortized weighted average period Weighted Average Amortization Period Weighted Average Amortization Period Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Adjustments for New Accounting Pronouncements Adjustments for New Accounting Pronouncements [Axis] Type of Adoption Type of Adoption [Domain] Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Range Statistical Measurement [Axis] Range Statistical Measurement [Domain] Maximum Maximum [Member] Sale of Stock Sale of Stock [Axis] Sale of Stock Sale of Stock [Domain] ATM Sales Agreement At The Market Sales Agreement [Member] At The Market Sales Agreement [Member] Public Stock Offering Public Stock Offering [Member] Public Stock Offering [Member] Underwritten Offering Over-Allotment Option [Member] Class of Stock [Line Items] Class of Stock [Line Items] Gross proceeds from sales of securities in registered offerings Gross Proceeds From Issuance Of Common Stock Gross Proceeds From Issuance Of Common Stock Aggregate commission rate Percentage Of Aggregate Commission Percentage of aggregate commission. Issuance of common stock via public offering, net (in shares) Stock Issued During Period, Shares, New Issues Net proceeds from sale of stock offering Sale of Stock, Consideration Received on Transaction Public offering price Sale of Stock, Price Per Share Offering expenses Offering Expenses Offering Expenses Warrants to purchase common stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Conversion of common stock Class Of Warrant Or Right, Conversion Of Common Stock Class Of Warrant Or Right, Conversion Of Common Stock Underwriters option to purchase additional shares of common stock and warrants period Underwriters Option To Purchase Additional Shares Of Common Stock Period Underwriters option to purchase additional shares of common stock period. Underwriters option to purchase additional shares (in shares) Underwriters Option To Purchase Additional Shares Underwriters option to purchase additional shares. Gross proceeds from offering of warrants Gross Proceeds From Offering Of Common Stock And Warrants Gross Proceeds From Offering Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Warrant, exercise price, decrease Warrant, Exercise Price, Decrease Deemed dividend from trigger of down round provision Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Estimated fair value of warrants Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Warrants exercised (in shares) Number Of Common Stock Warrants Exercised Number of common stock warrants exercised. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Weighted-average fair value of options granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Summary of Components of Loss from Continuing Operations Before Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Difference Between Provision for Income Taxes (Benefit) and the Amount Computed by Applying U.S. Federal Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Summary of Major Components of Company's Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Reconciliation of the Beginning and Ending Amount of Uncertain Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Organization and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Stock-based compensation Share-based Payment Arrangement, Noncash Expense Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Acquisition-related IPR&D Research and Development in Process Changes in operating assets and liabilities, net of impact of acquisition: Increase (Decrease) in Operating Capital [Abstract] Other receivables Increase (Decrease) in Other Receivables Prepaid expenses Increase (Decrease) in Prepaid Expense Other current assets Increase (Decrease) in Other Current Assets Other non-current assets and deferred charges Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Deferred grant funding Increase Decrease In Deferred Grant Funding Increase Decrease In Deferred Grant Funding Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Acquisition of Microchips cash Cash Acquired from Acquisition Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of Pear Tree and Hydra assets Payments For Asset Acquisition Payments For Asset Acquisition Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents, beginning of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of year Supplemental disclosure of non-cash operating, investing and financing activities: Supplemental Cash Flow Information [Abstract] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Microchips acquisition consideration paid in equity Business Combination, Consideration Transferred Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Eunice Kennedy Shriver National Institute Of Child Health And Human Development Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] Product and Service Product and Service [Axis] Product and Service Product and Service [Domain] ATM Sales ATM Sales [Member] ATM Sales [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Second Phase Of Research And Availability Of Funds Second Phase Of Research And Availability Of Funds [Member] Second Phase Of Research And Availability Of Funds [Member] Remaining Portion Of Research And Availability Of Funds Remaining Portion Of Research And Availability Of Funds [Member] Remaining Portion Of Research And Availability Of Funds [Member] Related Party Related Party [Axis] Related Party Related Party [Domain] National Institutes Of Health National Institutes Of Health [Member] National Institutes Of Health [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Warrant Warrant [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Revenue from grant for notice of awards Revenue from Contract with Customer, Excluding Assessed Tax Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Sales commissions and fees Sales Commissions and Fees Warrants to purchase shares Class of Warrant or Right, Outstanding Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Milestone payments, contingent amount Milestone Payments Contingent Amount Milestone payments, contingent amount. Period from first commercial sale Period From First Commercial Sale Period From First Commercial Sale License agreement, notice period of termination License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Research and development credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Capitalized research and development costs Deferred Tax Assets Capitalized Research And Development Cost Deferred Tax Assets Capitalized Research And Development Cost Other Deferred Tax Assets, Other Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Total deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Other Assets, Noncurrent Disclosure [Abstract] Prepaid insurance, long-term portion Prepaid Insurance Noncurrent Prepaid insurance noncurrent. Deposits Deposits Assets, Noncurrent Operating lease assets Operating Lease, Right-Of-Use Asset, Noncurrent Operating Lease, Right-Of-Use Asset, Noncurrent Total other non-current assets Other Assets, Noncurrent Schedule of Common Stock Outstanding Warrant to Purchase Shares Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Schedule of common stock reserved for future issuance. Payables and Accruals [Abstract] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Leases [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three Total future minimum lease payments Lessee, Operating Lease, Liability, Payments, Due Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total operating lease liabilities Operating Lease, Liability Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Beginning uncertain tax benefits Unrecognized Tax Benefits Current year - increases Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Prior year - reductions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Ending uncertain tax benefits Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Current Assets Other Current Assets [Member] Lease of Office Space Lease of Office Space [Member] Lease of Office Space [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Square feet of office space Net Rentable Area Renewal term of operating lease Lessee, Operating Lease, Renewal Term Operating lease discount rate Lessee, Operating Lease, Discount Rate Right-of-use asset Operating Lease, Right-of-Use Asset Current portion of lease liabilities Operating Lease, Liability, Current Operating lease, liability, noncurrent Operating Lease, Liability, Noncurrent Operating lease cost Operating Lease, Cost Operating lease, payments Operating Lease, Payments Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Statement of Financial Position [Abstract] Preferred stock, shares issued Preferred Stock, Shares Issued Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common stock, shares outstanding Prepaid clinical expense Prepaid Clinical Expense Prepaid Clinical Expense Prepaid insurance expense Prepaid Insurance Prepaid legal and professional expenses Prepaid Professional Expense Prepaid Professional Expense Total prepaid expenses Prepaid Expense, Current Income Taxes Income Tax Disclosure [Text Block] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding beginning balance (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding ending balance (in shares) Options exercisable at December 31, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options vested and expected to vest at December 31, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding beginning balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding ending balance (in usd per share) Options exercisable at December 31, 2018 (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options vested and expected to vest at December 31, 2018 (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Roll Forward Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term roll forward. Outstanding at December 31, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options exercisable at December 31, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options vested and expected to vest at December 31, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value Roll Forward Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value. Outstanding at December 31, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options exercisable at December 31, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options vested and expected to vest at December 31, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Summary of Stock Option Activity for 2015 Plan and Current Plan and Related Information Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees, and Non-Employee Directors Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Business Combinations [Abstract] Acquisitions Business Combination Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Beginning balance, shares Shares, Outstanding Issuance of common stock via public offering, net Stock Issued During Period, Value, New Issues Equity issued in consideration of acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Equity issued in consideration of acquisition Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Foreign currency translation adjustments Ending balance Ending balance, shares Warrants Expiring on December 1, 2021 Warrants Expiring On December One Two Thousand Twenty One [Member] Warrants expiring on december one two thousand twenty one. Warrants Expiring on December 6, 2021 Warrants Expiring On December Six Two Thousand Twenty One [Member] Warrants expiring on december six two thousand twenty one. Warrants Expiring on January 8, 2020 Warrants Expiring On January Eight Two Thousand Twenty [Member] Warrants expiring on january eight two thousand twenty. Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Warrants Expiring On February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Shares underlying outstanding warrants (in shares) Schedule of Other Non-Current Assets Schedule of Other Assets, Noncurrent [Table Text Block] Leased Properties Lessee, Operating Leases [Text Block] Receivables [Abstract] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] First Phase Of Research And Availability Of Funds First Phase Of Research And Availability Of Funds [Member] First Phase Of Research And Availability Of Funds [Member] Health Care Trust Fund Health Care Trust Fund [Axis] Health Care Trust Fund, Name Health Care Trust Fund, Name [Domain] Bill And Melinda Gates Foundation Bill And Melinda Gates Foundation [Member] Bill And Melinda Gates Foundation [Member] Grant Awards Grant [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Cash received from federal grant awards Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Deferred grant funding awards Deferred Grant Funding Current Deferred Grant Funding Current Schedule Of Business Combination Reverse Merger [Table] Schedule Of Business Combination Reverse Merger [Table] Schedule of business combination reverse merger. Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Pear Tree Pharmaceuticals Inc. Pear Tree Pharmaceuticals Inc [Member] Pear Tree Pharmaceuticals, Inc. Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Business Combination Reverse Merger [Line Items] Business Combination Reverse Merger [Line Items] Business combination reverse merger. Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Unamortized fair value of Cerulean stock options Business Combination Reverse Merger Unamortized Fair Value Of Stock Options Business combination reverse merger unamortized fair value of stock options. Goodwill impairment charge Equity issued in consideration of acquisition Potential cash payment to acquire business Potential Cash Payments To Acquire Business Potential Cash Payments To Acquire Business Business acquisition transaction value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Common stock issued to Microchips capital stock holders (in shares) Business combination shares issued (dollars per share) Business Acquisition, Share Price Contingent consideration, liability Business Combination, Contingent Consideration, Liability Contingent consideration Asset Acquisition, Contingent Consideration Asset Acquisition, Contingent Consideration Transaction costs Business Combination Reverse Merger Stock Purchase Transaction Cost Business combination reverses merger stock purchase transaction cost. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] SST Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Orbis Orbis [Member] Orbis [Member] MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Hammock Pharmaceuticals, Inc. Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Project Project [Axis] Project Project [Domain] Upon Achievement Of Specified Development And Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Related Party Transaction Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Upon Signing Of Development And Option Agreement Upon Signing Of Development And Option Agreement [Member] Upon Signing Of Development And Option Agreement [Member] Upon Completion Of Fifty Percent Development Not Later Than Six Months Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Type of Arrangement and Non-arrangement Transactions Arrangements and Non-arrangement Transactions Licensing Agreements Licensing Agreements [Member] Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Development And Option Agreement Development And Option Agreement [Member] Development And Option Agreement [Member] Juniper Pharmaceuticals, Inc. Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Clinical And Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Minimum Minimum [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product License agreement, termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. Milestone payments Research And Development Milestone Payment Research and development milestone payment. Commencement period for stage two upon achievement of stage one Commencement Period For Stage Two Upon Achievement Of Stage One Commencement Period For Stage Two Upon Achievement Of Stage One Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments License fee License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Defined contribution plan, employer matching contribution, percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Defined contribution plan, employer matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Measurement Frequency Measurement Frequency [Axis] Fair Value, Measurement Frequency Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Number of operating segments Number of Operating Segments Accumulated deficit Retained Earnings (Accumulated Deficit) Cash and cash equivalents Convertible Debt Working capital increase Working Capital Increase (Deficit) Working Capital Increase (Deficit) Operating income (loss) Letter of credit related to lease of real property Letters of Credit Outstanding, Amount Cash balance of financial institutions insured by federal deposits insurance corporation Cash, FDIC Insured Amount Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Grant funding recognized during period Grant Funding Recognized During Period Grant Funding Recognized During Period Stock options exercisable Income tax provision Income Tax Expense (Benefit) Unrecognized tax benefits Lease liability Accrued indemnification P\provisions Accrued Indemnification Provisions Accrued indemnification provisions. Assets Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other receivables Other Receivables, Net, Current Prepaid expenses Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Other non-current assets Total assets Assets Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred grant funding Total current liabilities Liabilities, Current Contingent consideration non-current Business Combination, Contingent Consideration, Liability, Noncurrent Lease liabilities long-term Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 10) Commitments and Contingencies Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock issued Preferred Stock, Value, Issued Common stock: $0.0001 par value, 120,000,000 shares authorized, 19,683,401 and 11,422,161 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively Common Stock, Value, Issued Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Additional Paid in Capital, Common Stock Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Exercise of Warrants Outstanding Exercise Of Warrants Outstanding [Member] Exercise of warrants outstanding. Exercise of Options Outstanding Exercise Of Options Outstanding [Member] Exercise of options outstanding. Common stock reserved for issuance (in shares) Other Non-Current Assets Other Assets Noncurrent Disclosure [Text Block] Other assets noncurrent disclosure. Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Future Minimum Lease Payment Lessee, Operating Lease, Liability, Maturity [Table Text Block] Subsequent Events Subsequent Events [Text Block] Stock-based Compensation Share-based Payment Arrangement [Text Block] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Loss before taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Accrued compensation and benefits expenses Employee-related Liabilities, Current Accrued legal and professional expenses Accrued Professional Fees, Current Accrued license expense Accrued License Expense Accrued License Expense Accrued clinical and related expenses Other Accrued Liabilities, Current Total accrued expenses Accounts Payable and Accrued Liabilities, Current Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Domestic Tax Authority [Member] State State and Local Jurisdiction [Member] Tax Credit Carryforward Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward, Name [Domain] Research Credit Carryforwards Research Tax Credit Carryforward [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Deferred tax valuation allowance Deferred tax assets, increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Net operating loss carryforwards Operating Loss Carryforwards Operating loss carryforward, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Net operating loss carryforwards expiration year Operating Loss Carryforwards Expiration Period Operating loss carryforwards expiration period. Operating loss carryforwards not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Research credit carryforwards Tax Credit Carryforward, Amount Research credit carryforwards expiration year Tax Credit Carryforward Expiration Period Tax credit carry forward expiration period. Tax cuts and jobs act of 2017, incomplete accounting, provision to income tax expense in continuing operations Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Accrued interest or penalties recorded related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unremitted earnings Unremitted Earnings Unremitted earnings. Grant Awards Grant Award [Text Block] Grant Award [Text Block]